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Protein S-nitrosation (SNO-protein), the nitric oxide-mediated posttrans-
lational modification of cysteine thiols, is an important regulatory
mechanism of protein function in both physiological and pathological
pathways. A key first step toward elucidating the mechanism by which
S-nitrosation modulates a protein’s function is identification of the tar-
geted cysteine residues. Here, we present a strategy for the simulta-
neous identification of SNO-cysteine sites and their cognate proteins to
profile the brain of the CK-p25–inducible mouse model of Alzheimer’s
disease-like neurodegeneration. The approach—SNOTRAP (SNO trap-
ping by triaryl phosphine)—is a direct tagging strategy that uses phos-
phine-based chemical probes, allowing enrichment of SNO-peptides
and their identification by liquid chromatography tandem mass spec-
trometry. SNOTRAP identified 313 endogenous SNO-sites in 251 pro-
teins in the mouse brain, of which 135 SNO-proteins were detected
only during neurodegeneration. S-nitrosation in the brain shows re-
gional differences and becomes elevated during early stages of neuro-
degeneration in the CK-p25 mouse. The SNO-proteome during early
neurodegeneration identified increased S-nitrosation of proteins impor-
tant for synapse function, metabolism, and Alzheimer’s disease pathol-
ogy. In the latter case, proteins related to amyloid precursor protein
processing and secretion are S-nitrosated, correlating with increased
amyloid formation. Sequence analysis of SNO-cysteine sites identified
potential linear motifs that are altered under pathological conditions.
Collectively, SNOTRAP is a direct tagging tool for global elucidation
of the SNO-proteome, providing functional insights of endoge-
nous SNO proteins in the brain and its dysregulation during
neurodegeneration.
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Protein S-nitrosation (SNO-protein), in which a cysteine (Cys)thiol is converted to a nitrosothiol (RSNO), is an important
posttranslational modification (PTM). Cys residues targeted for
S-nitrosation often impact enzyme activity, protein localization,
and protein–protein interactions (1). SNO begins with the pro-
duction of nitric oxide radicals (NO•) via conversion of L-argi-
nine to L-citrulline by nitric oxide synthase 1 (NOS1) (neuronal),
NOS2 (inducible), and NOS3 (endothelial). NO-mediated SNO
PTMs are thought to occur in vivo predominantly through
radical recombination between NO• and a thiyl radical,
transnitrosation by low-molecular weight NO carriers such as
S-nitrosoglutathione (GSNO), or protein-assisted transnitrosation
(2–8). In the healthy brain, low levels of NO and normal SNO
PTMs play important roles in regulating synaptic plasticity, gene
expression, and neuronal survival. In contrast, elevated NO levels
associated with aging and environmental stress have been linked
to neurological pathologies, including Alzheimer’s (AD), Parkin-
son’s, and Huntington’s disease (9). AD is the most prevalent form
of human dementia, with a frequency that progressively increases
in aging societies (10). A pivotal role in development and pro-
gression of late-onset AD, and other age-dependent dementias,
has been attributed to inflammatory and oxidative stress cascades
in the brain (11, 12), which are potentiated by elevated levels of
nitrosating and oxidizing species (13, 14).
Despite the biological importance of this PTM, significant
gaps exist regarding its in vivo specificity and origin. Character-
ization of endogenous proteins suggests that not all reduced Cys
residues on a given protein and not all Cys-containing proteins
are S-nitrosated, implying a biased selection. Although S-nitro-
sation has been frequently reported, the specific SNO residues
for many of the proteins have not been determined and can be
critical for determining their function. Currently, the identifica-
tion of a specific SNO residue involves an iterative combination
of mutagenic and mass spectrometry (MS)-based approaches. The
prototypical method for detecting SNO-proteins is the biotin-
switch technique (BST), which requires blocking of all free Cys-
thiols, followed by selective ascorbate reduction of SNO-Cys
residues that are biotinylated and isolated for analysis (9, 15–17).
One limitation of the BST is that false positives can occur
through incomplete blocking of free Cys-thiols, making them
difficult to distinguish from true SNO-Cys residues. The vari-
ability of the BST and similar methods has driven a search for
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alternative approaches for accurate SNO-Cys detection and
mapping.
In this context, we have developed a method that enables
global, facile, and high-throughput identification of endogenous
SNO-Cys residues. SNOTRAP (SNO trapping by triaryl phos-
phine) is a direct tagging technique that allows enrichment and
identification of SNO-proteins and their cognate SNO-sites.
Hyperactivation of cyclin-dependent kinase-5 (Cdk5) by its acti-
vator peptide, p25, leads to AD-like neurodegenerative pathology,
and inhibition of p25 activity ameliorates AD phenotypes (18–20).
The CK-p25 mouse model of AD-like neurodegeneration allows
temporal characterization of neurodegeneration through inducible
expression of the p25 activator peptide, leading to elevated amy-
loid-β levels and DNA damage, followed by synaptic loss, neuronal
death, and cognitive impairments (21–24). SNOTRAP was used
here to profile changes in the SNO-proteome of the CK-p25
mouse model of AD-like neurodegeneration and healthy con-
trols (21, 22). Our data provide insights into signaling pathways
that may be perturbed by SNO in the neurodegenerating brain
that could provide novel avenues for AD-related therapies.
Results and Discussion
Site-Specific Identification of SNO-Peptides. SNOTRAP is a proteo-
mic extension of the method described earlier for detecting low-
molecular–weight RSNOs using phosphine ester reagents (25).
The SNOTRAP probe consists of a triphenylphosphine thioester
linked to a biotin molecule through a polyethyleneglycol (PEG)
spacer group. The method is based on reaction of the triphenyl-
phosphine thioester with RSNO and subsequent biotin-mediated
affinity capture of labeled peptides and/or proteins. The probe
reacts with SNO groups, first yielding an azaylide intermediate,
which through a properly positioned electrophile (thioester), rear-
ranges to form a disulfide–iminophosphorane (Fig. S1A) (25, 26).
The reaction proceeds through a Staudinger ligation-type mecha-
nism that retains the nitrogen atom and thiol moiety, allowing
unequivocal confirmation of specific SNO-sites in the peptide.
Overall, the workflow consists of three main steps: (i) blocking of
reduced Cys residues with iodoacetamide (IAM), (ii) capture and
release of SNO-proteins or SNO-peptides, and (iii) nanoflow liq-
uid chromatography (nLC)–MS/MS analysis (Fig. 1A). Blocking
with IAM prevents transnitrosation during sample preparation,
ensuring that the in vivo location of SNO-sites is retained.
To identify SNO proteins, and their cognate SNO-sites, we used
two complementary approaches (Fig. 1A). The first was to identify
SNO proteins, whereby SNOTRAP-modified proteins were
enriched by streptavidin affinity (Fig. 1A, approach A). Tryptic
peptides were analyzed by LC–MS/MS, and proteins were iden-
tified by database searching. Identification of SNO-sites using
approach A was hindered due to extra features in the mass spectra
arising from the SNOTRAP tag. These features include (i) limited
ionization due to the added bulkiness of the triphenylphosphine–
PEG–biotin (SNOTRAP) tag, (ii) added features to the collision-
induced dissociation (CID) spectra such as tag-related fragment
ions and corresponding neutral losses, and (iii) ion suppression
by the dominant ions created by the SNOTRAP tag.
Consequently, a second approach (B) was developed that
substitutes N-ethyl maleimide (NEM) for the bulky SNOTRAP
tag, which allows direct detection of SNO-sites by MS. Briefly,
proteolytic digestion is performed before streptavidin capture to
isolate modified peptide fragments that contain the SNOTRAP
tag rather than intact SNO-proteins. (Fig. 1A, approach B). The
SNOTRAP tag is subsequently cleaved, the peptides eluted with
triscarboxyethylphosphine (TCEP), and the liberated Cys labeled
with NEM before nLC–MS/MS. This strategy selectively en-
riches only SNO-containing peptides, which reduces the com-
plexity of the nLC separation and improves the detection of
SNO-sites. The diagnostic fragment ions (DFIs) at m/z 126.0550,
125.0477, and 158.0276 verify that this was a SNO-peptide
(Fig. 1B and Fig. S1B) (27, 28). Our criteria for identification
of SNO-proteins required detection of two or more tryptic
peptides per SNO-protein using approach A and the SNO-Cys
site-specific peptide identification using approach B.
Cortical tissues from CK-p25 mice were analyzed independently
by capture of SNO-proteins (approach A) and SNO-peptides (ap-
proach B), using multiple biological replicates. Proteins were
identified by Spectrum Mill (Agilent) for both approaches and
pooled for analysis. By matching peptides for a given protein using a
combination of both approaches, we identified 251 proteins
(Dataset S1). DFIs in MS/MS spectra using approach B pin-
pointed 313 SNO-sites within these proteins (Dataset S1; MS/MS
spectra can be viewed at web.mit.edu/toxms/www/SNOTRAP/).
Detection of SNO-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) on Cys-150, as previously reported by others using
independent approaches, validated the robustness of the protocol
(Fig. S1 B and C) (16, 29). SNOTRAP also detected previously
unidentified SNO-sites, such as SNO-Cys284 of gephyrin (GPHN1),
indicating the sensitivity of the method (Fig. S1 B and C). The
SNOTRAP approach was able to detect and identify a large number
of endogenous SNO-proteins and SNO-sites in the brain and is
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Fig. 1. Site-specific identification of SNO-protein. (A) Schematic for selective la-
beling and analysis of SNO-proteins. Unmodified Cys-thiols were blocked,
and SNO-Cys sites were labeled with the b-SNOTRAP probe. For approach A,
b-SNOTRAP–tagged proteins were enriched using streptavidin beads, washed,
eluted with denaturing conditions, trypsin-digested, and analyzed by LC–MS/MS.
For approach B, the proteome was trypsin-digested, and b-SNOTRAP–tagged
peptides were enriched using streptavidin beads, followed by release of
the biotin linker by TCEP; alkylated with NEM; and analyzed by LC–MS/MS.
(B) Generation of DFIs from NEM-modified peptides.
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complementary to previous reports for mouse, rat, and human (Fig.
S1F) (16, 30–32).
To control for false positives that may result from nonspecific
interactions with the streptavidin beads, pretreatment with TCEP,
UV, and ascorbate-Cu were used to displace SNO PTMs before
reaction with the SNOTRAP probe and analyzed by MS (Fig.
S1D). Samples pretreated with TCEP were also analyzed by
Western blot (Fig. S1E). Approximately 3% of peptides and 5% of
proteins (Materials and Methods) were identified as false positives
(present in both the test samples and negative controls) and were
removed from further analysis.
SNO-Proteins Identified During Early Neurodegeneration. To de-
termine temporal changes during neurodegeneration of SNO-
proteins and their cognate SNO-Cys sites, we used the CK-p25
mouse model of AD-like neurodegeneration. CK-p25 mice show
early signs of neurodegeneration, including DNA damage, in-
creased amyloid-β, and the onset of neuroinflammation, before
behavior abnormalities (Fig. 2A) (21, 22, 33). After 6 wk of p25
induction, mice exhibit learning and memory impairments and
signs of advanced neurodegeneration, such as neuronal death
and reduced synapse number (23, 24). To assess changes in SNO
in the brain during the progression of neurodegeneration, we
first measured GSNO levels in the hippocampus, cortex, and
cerebellum of CK-p25 mice and p25 control littermates during
early (2 wk) and later (6 wk) stages of neurodegeneration. In
control mice, the levels of GSNO were highest in the cerebellum,
reflecting previous observations that NOS1 expression is high in
the cerebellum of adult mice (13). During early stages of neu-
rodegeneration, GSNO increased in the cortex and the hippo-
campus to levels (twofold and threefold, respectively) that either
resembled or surpassed that of the cerebellum (Fig. 2B). In-
creased SNO levels in 2-wk–induced CK-p25 mice correlate with
elevated DNA damage previously observed in these regions (24).
In the cerebellum, no increase in GSNO was observed at 2 wk,
which likely reflects the low level of p25 induction in this brain
region (21). GSNO levels in the hippocampus and cortex during
a later stage of neurodegeneration return to levels similar to
controls. Low levels of NO lead to S-nitrosation, whereas high
levels cause cell death (14). The reduction of GSNO levels at a
later stage of neurodegeneration could reflect a change in the
proportion of cell types in these regions, including a loss of
neurons and gliosis (21), although the possibility of lowered SNO
production cannot be excluded. Collectively, our results suggest
that elevated GSNO in the hippocampus and cortex is an early
indicator of neurodegeneration and that elevated SNO may be a
driving mechanism for disease progression.
To assess the endogenous SNO-proteome profile in the brains
of CK-p25 and control mice during early stages of neuro-
degeneration (2 wk), SNO-proteins were isolated and identified
in the cortex, hippocampus, and cerebellum. We detected a
larger number of SNO-proteins and SNO-sites in CK-p25 mice
compared with controls. In control mice, 152 SNO-sites and 116
SNO-proteins were identified, compared with 292 SNO-sites and
237 SNO-proteins in the CK-p25 mice (Dataset S1). The largest
increase in CK-p25–specific SNO-proteins was detected in the
cortex (Fig. 2C), which is consistent with elevated levels of GSNO
during early neurodegeneration (Fig. 2B). Of the 212 SNO-proteins
identified in the cortex, almost two-thirds (64%) were detected only
in the CK-p25 mice (Fig. 2C and Dataset S1). A total of 264 SNO-
Cys sites were identified in the cortex, of which 160 (61%) were
found exclusively in CK-p25 mice (Dataset S1).
We detected 89 SNO-proteins in the hippocampus. Although
AD pathology is readily observed in the hippocampus and our
data show elevated GSNO, the majority of detected SNO-proteins
(70%) were common between CK-p25 and controls (Fig. 2C). The
reduced number of proteins may reflect a limitation in the total
protein we obtained from the hippocampus (Fig. 2C and Dataset
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Fig. 2. Altered levels of SNO are detected in CK-p25 mice during early
stages of neurodegeneration. (A) Timeline of the pathological progression
of the CK-p25 mouse model of neurodegeneration. (B) GSNO concentration
(μM) in the cortex, hippocampus, and cerebellum of control or CK-p25 mice
following induction of p25 expression for 2 wk or 6 wk. Two-way ANOVA;
Dunnett’s multiple comparisons; ****P < 0.0001, ***P < 0.001, *P < 0.05;
n = 4 for 2-wk samples and n = 3 for 6-wk samples; mean ± SEM. (C) Number
of SNO-proteins identified in the cortex, hippocampus, and cerebellum of
control and CK-p25 mice following 2-wk induction. (D) Gene ontology
analysis of total SNO-proteins identified in the cortex of control mice (dark
blue, KEGG pathways; light blue, BPs). (E) Gene ontology analysis of SNO-
proteins exclusively identified in the cortex of CK-p25 mice following 2-wk
induction (dark red, KEGG pathways; light red, BPs).
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S1). The cerebellum has an approximately equal distribution of
SNO-proteins (32%, 45%, and 23%) between control and CK-p25
mice (Fig. 2C and Dataset S1) and mirrors observations of little
change in GSNO for this brain region (Fig. 2B).
Bioinformatic Analysis of the S-Nitrosoproteome. To decipher the
possible impact of SNO-proteins on molecular and cellular sys-
tems during early neurodegeneration, we performed gene ontol-
ogy analysis of biological processes (BPs) and KEGG pathways
using the total control SNO-proteome (Fig. 2D) and the CK-p25–
specific SNO-proteome (Fig. 2E) of the cortex (34, 35). Gene
ontology clusters associated with synaptic functions were observed
for SNO-proteins in control and CK-p25 mice (BP_Synaptic
transmission and BP_Transmission of nerves impulse). The
synaptic protein synaptophysin was validated by SNOTRAP-
Western blot (Fig. S2A). Pathways associated with cognition
were identified in both control (KEGG_Long-term potentiation
and BP_Behavior) and CK-p25 mice (BP_Learning or memory).
Collectively, these data suggest that regulation of synaptic SNO-
proteins is important for normal neuronal functions associated
with learning and memory and also that the synapse is vulnerable
to aberrant SNO-signaling. NOS1, the major source of neuronal
NO, is tethered to the synapse by postsynaptic density protein 95
(PSD95; also known as DLG4) (36). Although we did not detect
SNO-PSD95 by MS, SNOTRAP-Western blot analysis shows a
strong elevation of SNO-PSD95 in CK-p25 mice (Fig. S2B), in-
dicating a susceptibility of the synapse to increased SNO during
early neurodegeneration.
SNO-proteins linked to AD were detected in the CK-p25 cortex
and not in controls, as identified by the AD KEGG pathway (Fig.
2E; GRIN2B, TAU, GSK3β, LRP1, NDUFS1, COX6B1, and
GAPDH). NOS1 is activated by N-methyl-D-aspartate receptor
(NMDAR)-mediated influx of Ca2+; subsequent S-nitrosation of
NMDAR is thought to modulate its activity. However, hyper-
excitation of NMDAR leads to excessive Ca2+ signaling and ele-
vated NO production, conditions thought to occur during
neurodegeneration. This could explain detection of SNO-GRIN2B,
a subunit of the NMDAR, in the CK-p25 mice. Amyloid activation
of the NMDAR can increase p25 production, possibly providing a
feed-forward mechanism for SNO production (18). NMDAR-
mediated p25 production and Cdk5 activation is thought to increase
glycogen synthase kinase-3β (GSK3β) and TAU (Mapt) phos-
phorylation, two key mediators of neuronal death in AD, both of
which we identified in the CK-p25 mice. Elevated SNO-GSK3β
was validated by SNOTRAP-Western blot analysis (Fig. S2A).
Cdk5 itself has been reported to be S-nitrosated, which enhances
its serine/threonine kinase activity (37). Although SNO-Cdk5 was
not detected by MS, it was elevated in CK-p25 mice (shown by
SNOTRAP-Western blot; Fig. S2B), possibly contributing to ele-
vated Cdk5 activity and acting as a feed-forward mechanism
during neurodegeneration. In addition, protein kinase C (PKC)
epsilon and gamma isoforms (Prkce and Prkcg) were S-nitrosated in
CK-p25 mice. PKC inhibits GSK3β and promotes nonamyloidogenic
processing of amyloid precursor protein (APP) through activa-
tion of α-secretase (38). S-nitrosation inhibits PKC activity (39,
40) and therefore may reduce APP processing through the
nonamyloidogenic α-secretase pathway.
Additional AD-related pathways impacted by SNO during neuro-
degeneration included apolipoprotein E (ApoE)-mediated amyloid
clearance (SNO-LRP1) and mitochondrial dysfunction (SNO-
NDUFS1 and SNO-COX6B1, which are components of CxI and
CxIV of the respiratory chain). Furthermore, Gene Ontology (GO)
analysis indicated that proteins regulating glycolysis were enriched
in the CK-p25–specific SNO-proteome (BP_Monosaccharide me-
tabolism), suggesting that elevated SNO may affect metabolic
processes during early neurodegeneration. In particular, GAPDH
was S-nitrosated in CK-p25 mice but not in control mice and was
validated by SNOTRAP-Western blot (Fig. S2A). Nuclear SNO-
GAPDH transnitrosates SIRT1, HDAC2, and DNA-PK (DNA-
dependent protein kinase, catalytic subunit), impacting metabolic
pathways, aging, and chromatin remodeling (41–43). HDAC2 was
not detected in our SNO-proteome, although we observed ele-
vated SNO-HDAC2 in CK-p25 mice by SNOTRAP-Western blot
(Fig. S2B).
Linear Motifs for S-Nitrosation. Recent studies indicate that the
specificity of SNO-Cys sites may be dependent on the spatial
proximity of charged amino acids, which are hypothesized to
CK-p25
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9
A
B
Fig. 3. SNO-site linear motif analysis indicates differential preference for
SNO-Cys sites during early neurodegeneration. (A) Linear motif generated
by pLOGO using sequences flanking SNO-Cys sites detected in control mice.
(B) Linear motif generated by pLOGO using sequences flanking SNO-Cys sites
exclusively detected in 2-wk–induced CK-p25 mice.
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Fig. 4. Pathways affected by S-nitrosation during neurodegeneration.
(A) SNO-LRP1 and SNO-PKC isoforms were identified in CK-p25 mice after
2-wk induction and have been implicated in secretase processing of APP and
amyloid clearance. (B) SNO-GSK3β and SNO-TAU were identified in CK-p25
mice after 2-wk induction and have been implicated in neurofibrillary tangle
formation and AD pathology. The functional implications of previously un-
identified SNO-proteins are represented with a question mark.
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allow protein–protein interactions that facilitate transnitrsation
(29, 44). To elucidate common features of SNO-Cys sites, we
used the probability LOGO (pLOGO) tool to analyze flanking
sequences of SNO-Cys residues for linear motifs (45). Motif
analysis of SNO-Cys sites in control and CK-p25 mice revealed
an overrepresentation of charged flanking amino acids; however,
this was not consistent for all SNO-Cys sites (Fig. 3 A and B).
Specifically, in control mice, basic residues Arg (R) and Lys (K)
were overrepresented at the –6, –4, +1, +3, +4, and +5 positions
(Fig. 3A); these residues may be required for base-catalyzed
transnitrosation (1, 46). To test the robustness of the motif, we
performed pLOGO analysis using an independently published
SNO-proteome from brains of wild-type (C57BL/6J) mice (47)
and found an enrichment of the basic residues—Lys (K), Arg
(R), and His (H)—surrounding the SNO-Cys position (Fig. S2C,
–6, –5, –1, +3, and +4). In the CK-p25 mice, we observed Lys (K)
basic residues at the –5 and +4 positions and Glu (E) and Asp
(D) acidic residues at the –6, –4, and +5 positions (Fig. 3B). This
motif may represent charge clustering and has been previously
proposed to allow acid–base catalysis for nitrosation (base) and
denitrosation (acid) of Cys residues. Despite these observations,
many SNO-Cys sites identified in both control and CK-p25 mice
did not have charged amino acids within a proximal location of the
primary sequence. Previous studies indicate that tertiary structural
elements may be required for localizing charged residues to SNO-
Cys sites for many proteins (29, 44). Collectively, these data sug-
gest that the specificity for S-nitrosation of a subset of Cys may be
dependent on proximal charged amino acids, which possibly pro-
vide docking sites for nitrosating and denitrosating agents (29).
Conclusion
Through development of SNOTRAP, a direct SNO-tagging MS
method for detecting both small and large molecular RSNOs, we
identified an expanded endogenous SNO-proteome in the mouse
brain. We identified the hippocampus and cortex as regions
subjected to elevated levels of SNO during early stages of neu-
rodegeneration that precede the onset of detrimental behavioral
changes. The identification of SNO-PKC and SNO-LRP1 during
neurodegeneration suggests that elevated SNO may impact amy-
loid processing and clearance, thus contributing to amyloid plaque
deposition (Fig. 4A). Furthermore, detection of SNO-GSK3β and
SNO-TAU in the CK-p25 mice indicates that aberrant SNO sig-
naling may affect neurofibrillary tangle formation, another hall-
mark of AD pathology (Fig. 4B). The susceptibility of multiple
proteins to S-nitrosation during early neurodegeneration relevant
to synaptic function, metabolism, and AD pathology may drive
cellular pathologies observed at later stages, such as neuronal
loss, reduced synapse integrity, and ultimately memory impair-
ment (Fig. 4 A and B). Increased protein aggregation and cell
death linked to SNO-proteins in CK-p25 mice likely lead to ac-
tivation of inflammatory responses, an important component of
AD pathology and progression (33). The SNOTRAP strategy
provided a comprehensive assessment of S-nitrosation in the
neurodegenerating brain that can be applied to multiple cellular
and disease contexts and has therapeutic potential for biomarker
discovery and drug development.
Animals. All mouse experiments were approved by the Commit-
tee on Animal Care of the Division of Comparative Medicine at
Massachusetts Institute of Technology.
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Materials and Methods
Reagents. Chemical reagents were obtained from commercial
sources (Sigma-Aldrich for chemicals,Cambridge IsotopeLaboratories
for deuterated solvents, Isotec for 13C2,
15N-labeled G*SH, Cre-
ative PEGWorks for maleimide–PEG–maleimide, and Chem-
Pep, Inc., for biotin–PEG3–propionic acid) and were used
without additional purification. Sequencing-grade modified
trypsin was obtained from Promega. Complete protease inhibitor
mixture was from Sigma. Extraction and silica chromatography
solvents were reagent grade. LC–MS and HPLC solvents were
HPLC grade. Acetonitrile was distilled for HPLC and LC–MS.
Distilled water was obtained in house and redistilled for HPLC
and LC–MS experiments. Vivaspin 3,000, 10,000, and 30,000
molecular-weight cutoff (MWCO) membrane filters were from
Sartorius Stedim NA. The primary antibodies used were as follows:
Synaptophysin (Sigma, S5768), GAPDH (Cell Signaling Tech.,
2118), Gsk3b (R&D), phosphatase and tensin homolog (PTEN)
(Cell Signaling Tech., 9552), Cdk5 (Cell Signaling Tech., 2506),
Stargazin (Santa Cruz, sc-374123), HDAC2 (Cell Signaling Tech.,
2540), and PSD95 (NeuroMab, P78352). Secondary HRP-
conjugated antibodies were purchased from Santa Cruz Bio-
technology (sc-2030 and sc-2005). ECL reagent was from GE
Healthcare (RPN2232). Unless otherwise stated, all sample
preparations, nitrosothiol preparations, and SNO-probe reac-
tions were carried out in the dark at room temperature. For
NMR analysis, 1H NMR spectra were recorded on Bruker
Avance-600 and Varian Inova-500 instruments at 600.13 and
500.13 MHz, respectively. The 13C NMR spectra were recorded
on a Varian Inova-500 instrument operating at 125.76 MHz. 31P
NMR spectra were recorded on a Varian Inova-500 instrument
operating at 202.46 MHz, and 31P chemical shifts are relative to
3% (vol/vol) H3PO4 (δ = 0 ppm) contained in a concentric in-
ternal capillary (Wilmad). NMR spectra were obtained using
Bruker 5-mm TXI cryo-probes and Varian 5-mm pulsed-field
gradient (PFG)-probes held at 22 °C unless otherwise stated.
Animals.All mouse experiments were approved by the Committee
on Animal Care of the Division of ComparativeMedicine at MIT.
Adult (2.5–3 mo old) male double-transgenic CK-p25 mice and
respective p25 control littermates were used (21). Tissue was
collected at 2 or 6 wk after induction of p25 expression. Three
brain regions were dissected from each mouse (cortex, hippo-
campus, and cerebellum). Dissections were performed on ice,
immediately flash frozen in liquid nitrogen, and stored at –80 °C.
Each biological replicate represents data obtained using tissue
from an individual mouse. For the GNSO experiments, four
biological replicates were used per group for 2-wk induction, and
three biological replicates were used per group for 6-wk in-
duction. For MS analysis, three biological replicates and two
technical replicates were used per group for both method A and
method B, and each sample was preseparated into five fractions.
Synthesis of SNOTRAP-Biotin. To a stirred 2-(diphenylphosphino)-
benzenethiol (48, 49) (100 mg, 0.34 mmol) in dry DMF (5 mL) we
added biotin–PEG3–propionic acid (100 mg, 0.22 mmol; ChemPep,
Inc.), N,N’-dicyclohexylcarbodiimide (70 mg, 0.34 mmol), and di-
methylaminopyridine (4 mg, 0.03 mmol) successively. The resulting
mixture was stirred for 7 h at room temperature, and the resulting
clear solution was then concentrated under reduced pressure and
purified by flash chromatography (hexane/EtOAc/MeOH gradient)
to give the desired product (yield 30%). The SNOTRAP probe
was repurified on an 1100 HPLC system with a photodiode array
UV detector at 254 nm (Agilent Technologies). HPLC columns
and solvent systems were as follows: A semipreparative Phe-
nomenex Luna C18 (25 cm × 9.4 mm, 10 μm) column was eluted
with a linear gradient of 0.1% formic acid in water (A) and
acetonitrile (B) at a flow rate of 2.5 mL/min. Solvent composi-
tion was initially at 40% for 5 min, 70% at 10 min, 90% at 20 min,
and then further to 95% B over 8 min: 1H NMR (500 MHz,
CD3CN, δ), 7.42–7.38 (m, 9H), 7.23–7.18 (m, 4H), 7.84 (m, 1H),
4.60–4.51 (m, 2H), 3.67–3.51 (m, 12H), 3.2 (m, 3H), 2.8 (m, 2H),
2.55 (t, 2H), 2.15 (t, 2H), 1.57–3.51 (m, 6H); 13C NMR (125 MHz,
CD3CN, δ), 199.19, 172.5, 164.5, 144.8, 138.1, 137.0, 134.8, 129.9,
129.6, 129.6, 118.3, 69.2, 63.1, 62.3, 45.9, 42.5, 38.2, 27.1, 23.1,
22.5; 31P NMR (202 MHz, CD3CN, δ), −10.3; and HRMS-ESI+
(m/z) [M + H+]+ calculated for C37H47N3O6PS2, 724.2638, and
found, 724.2632.
Sample Preparation for Tissue GSNO Analysis. Samples were first
spiked with 500 fmol of isotopically labeled internal standard
( 13C2,
15N-labeled G*SNO) and mixed with maleimide–PEG–
maleimide (20 mM, Creative PEGWorks) in PBS buffer con-
taining 1 mM EDTA. For complete cell lysis, samples were sub-
jected to three freeze/thaw cycles (dry ice to RT) with frequent
vortexing. Lysed samples were kept 15 min at room temperature
to allow complete blocking by maleimide-PEG-maleimide. Sam-
ples were centrifuged (16,000 × g, 10 min at 4 °C) to remove cell
debris, followed by filtration using 3,000 MWCOmembrane filters
(15,000 × g, 15 min at 4 °C). The filtrate (low-molecular weight
fraction) was then treated with the phosphine probe 3, as de-
scribed in an earlier publication (3 mM final concentration,
prepared by dissolving 4 mg of phosphine in 400 μL of 2:1 ace-
tonitrile/methanol mixture) (25). The resulting clear solution was
then freeze-dried to a final volume of 30 μL, and 8 μL was in-
jected into the LC–MS/MS. To generate negative controls, the
low molecular weight (LMW) filtrate was treated with 3 mM
DTT (15 min, 24 °C).
Endogenous GSNO Quantification. LC–MS quantitation was per-
formed by multiple-reaction monitoring (MRM), using the in-
ternal standard (G*SNO). A method calibration curve for LC–
MS/MS was obtained by spiking 500 fmol of 13C2,
15N-labeled
internal standard (G*SNO) into the reaction between phosphine
3 (5 mM) and GSNO standards (0–10 pmol, in PBS buffer
containing 1 mM EDTA). Regression analysis of the relative re-
sponse ratio, calculated from LC–MS/MS peak area ratios cor-
responding, respectively, to analytes and internal standards, was
then used to calculate the amount of GSNO (in pmols). This was
then multiplied by 3.8 (total volume 30 μL/8 μL injection to a MS
of 3.8) to obtain the total amount of analyte in the cell lysate.
The GSNO concentration was determined by dividing the total
amount of analyte (pmol) per million cells by the wet weight per
million cells (mg), assuming that the wet weight of cells (10
million) was equal to the weight of water (i.e., 1 mg = 1 μL).
ESI+–QqQ–MS Analyses. MRM and precursor-ion analyses were
carried out in positive-ion mode, as described earlier (25), using
an Agilent 1200 capillary HPLC system with an Agilent Triple
Quad LC/MS (model 6430). The chromatography was done on an
Agilent Eclipse XDB-C18 reverse-phase column (1.0 mm × 50 mm,
3.5 μm) with acetonitrile/water/formic acid gradients at 20 μL/min.
The instrument parameters were optimized for maximum response
during infusions of standard solutions.
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Isolation and Preparation of Mouse Brain Protein Homogenates. In-
tact brains were collected, immediately frozen in liquid nitrogen,
and stored at −80 °C. Isolated brain regions (cerebral cortex,
hippocampus, and cerebellum) were homogenized into 3 mL
lysis buffer (250 mM Hepes–NaOH, pH 7.7, containing 1 mM
diethylene triamine pentaacetic acid, 0.1 mM neocuproine, 1%
Triton X-100, 20 mM IAM, and protease inhibitors) on ice using
a Teflon pestle and a Jumbo Stirrer (Fisher Scientific). The
homogenates were centrifuged at 10,000 × g for 10 min at 4 °C.
The soluble protein fraction was collected, and the protein con-
centration was determined by the Bradford assay. Each sample
consisted of 2 mg of protein in 4 mL of lysis buffer (0.5 mg/mL).
Lysates were then split into equal aliquots. Negative controls were
generated by treatment with 10 mM TCEP for 30 min at room
temperature or with Cu-ascorbate. Following treatment with
2.5% SDS (final) and 300 mM IAM in 250 mM Hepes, pH 7.7,
buffer, samples were alkylated by incubation in a Thermomixer
in the dark at 37 °C and shaking for 30 min. To minimize sample
loss during sample processing, filter-aided sample preparation
(FASP) was used to remove excess reagents and the MWCO
filter was used as a reaction vessel (50). After alkylation, excess
IAM reagents were removed by buffer exchange with 8 M urea
three times and Milli-Q water once by centrifugation at 4,000 × g
for 30 min at 4 °C with 10,000 MWCO spin filters (Sartorius
Corporation).
Probe Labeling. SNOTRAP stock solutions [in 40% acetonitrile
(ACN)] were added to all samples to reach a final concentration
of 1.2 mM (in 25 mM Hepes buffer at pH 7.7) to selectively
convert SNO to stable disulfide–iminophosphorane. Samples
were incubated with SNOTRAP solution at room temperature
for 2 h for complete labeling. Excess reagent was removed by
three washes with 25 mM Hepes, pH 7.7, buffer and centrifuged
at 4,000 × g for 30 min at 4 °C with 10,000 MWCO spin filters.
Streptavidin Affinity Chromatography of SNOTRAP-Derivatized SNO-
proteins and Protein Digestion. Streptavidin was used to enrich for
SNOTRAP-derivatized proteins according to the protocol de-
tailed in Slade et al. (51). Briefly, following addition of the
samples to the streptavidin columns, the columns were washed
with PBS/CHAPS and distilled water, eluted with TFA/acetoni-
trile, and then frozen, lyophilized, and stored at –20 °C. In-
solution protein digestion (in 25 mM Hepes, pH 7.7, buffer) for
each sample was carried out in the dark at 37 °C for 3 h by
adding 8.8 μg trypsin (sequencing grade-modified trypsin was
obtained from Promega) and 1 mM CaCl2 to each sample. The
digests were transferred to 30-kDa cutoff filters (previously
rinsed with methanol and washed with water) to remove trypsin
and other higher molecular-weight components. Peptide-con-
taining fractions were desalted using Agilent 100-μL C18 Bond
Elut Zip tips and eluted with step gradients of acetonitrile
fractions (20%, 40%, 60%, 80%, and 100%). Samples were
reduced by Speedvac to less than 5 μL and adjusted to 10 μL
with Millipore water. Eluted peptides (5 μL) were analyzed by
LC–MS/MS, as described in MS Analysis for Protein Identifi-
cation.
Protein Digestion and SNOTRAP-Biotin–Streptavidin Affinity Peptide
Capture. For peptide-level enrichment, in-solution protein di-
gestion (in 25 mM Hepes, pH 7.7, buffer) for each sample was
carried out in the dark at 37 °C for 3 h by adding 8.8 μg trypsin
and 1 mM CaCl2 to each sample. The digests were transferred
to 30-kDa cutoff filters (previously rinsed with methanol and
washed with water) to remove trypsin and other higher molecular-
weight components. The filtrate containing the biotinylated pep-
tides was recovered and incubated with Neutravidin beads (200 μL
slurry per milligram initial protein; washed with 10 volumes of
0.1 M ammonium bicarbonate) for 2 h at room temperature under
gentle rocking. Samples were centrifuged at 1,000 × g for 4 min,
and the unbound fraction was removed. The beads were washed
four times with 2.5 volumes of 1 M ammonium bicarbonate con-
taining 50 mM NaCl, four times with 2.5 volumes of 0.1 M am-
monium bicarbonate, two times with 2.5 volumes of 0.025 M
ammonium bicarbonate, and finally four times with deionized
water. Between each wash, beads were rocked for 2 min and
centrifuged at 1,000 × g for 1 min. Bound peptides were eluted
with 5 mM of TCEP by shaking for 30 min at room temperature.
Eluted, Cys-containing peptides were alkylated using 100 mM
NEM. Peptides containing fractions were desalted using Agilent
100-μL C18 Bond Elut Zip tips and eluted to a gradient of aceto-
nitrile fractions (20%, 40%, 60%, 80%, and 100%). Samples were
reduced in volume by Speedvac to less than 5 μL and adjusted to 10
μL with Millipore water. Eluted peptides (5 μL) were analyzed by
LC–MS/MS, as described in MS Analysis for Protein Identification.
Western Blot Detection of Endogenous S-Nitrosoproteome in Mouse
Brains. To detect endogenous SNO-proteins, control and CK/p25
samples were labeled using SNOTRAP as described above. Ultra-
Link Immobilized Streptavidin beads (Thermo Scientific, 20349)
(100 μL of slurry) were first washed with 25 mM Hepes buffer (pH
7.7) (3 × 200 μL), and probe-labeled proteins were added to the
beads and pull-down was carried out for 1 h in pull-down buffer (25
mM Hepes, 150 mM NaCl, 0.05% SDS) at room temperature.
Then beads were washed with (3 × 200 μL) wash buffer (25 mM
Hepes buffer, pH 7.7, 0.1% SDS), (3 × 200 μL) 25 mM Hepes
buffer (pH 7.7), and finally (2 × 200 μL) ddH2O. Biotinylated
proteins were eluted from beads by boiling in the presence of
electrophoresis sample loading reducing buffer (contains
DTT), followed by SDS/PAGE and transfer to polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked and
incubated with monoclonal/polyclonal antibody, followed by
respective secondary HRP-conjugated antibodies. Protein
bands were visualized with ECL reagent, and bands were imaged
using Fluorchem 8900 (Alpha Innotech). To detect endogenous
SNO-biotinylated proteins, equal amounts of SNOTRAP-la-
beled proteins from control and CK/p25 samples (10 μg) were
loaded into the SDS/PAGE gel for electrophoresis. The proteins
were transferred into PVDF membranes, and the blot was
probed against streptavidin–HRP to visualize total bio-
tinylated proteins. The bands were captured using Fluorchem
8900 from Alpha Innotech. For negative controls, SNO modi-
fications were reduced using TCEP and processed as with
SNOTRAP labeling.
MSAnalysis for Protein Identification.These were carried out on the
Agilent HPLC-Chip/MS System, consisting of a micro-auto-
sampler with a thermostat (set to 4 °C), a capillary and nanoflow
pump with microdegasser, and the Chip-Cube that interfaces LC
modules and the MS instrument. HPLC-grade water [0.1%
formic acid (FA)] and ACN (0.1% FA) were used as mobile
phases A and B, respectively. Separations were conducted on a
Polaris-HR-Chip 3C18 (150 mm × 50 μm) 80A 3-μm C18 chip
with 360 nL trap column (Agilent Technologies). Sample anal-
ysis used a 60-min gradient operating on the nanopump. The
capillary pump provides a constant flow of 2 μL/min for delivery
of samples from the autosampler to the HPLC–Chip interface.
Two LC gradients were used. Mobile phases were 0.1% formic
acid in HPLC-grade water (phase A) and 0.1% formic acid in
acetonitrile (phase B). In MS approach A, the gradient started at
3% B at 300 nL/min for 5 min and increased to 30% B from 2 to
102 min, to 60% B at 112 min, to 90% B at 125 min, and to 97%
at 126 min, was held for 4 min, and was followed by a 10-min
postrun at 3% B. For MS approach B, the gradient started at 3%
B at 300 nL/min for 5 min and increased to 30% B from 2 to 35
min, to 60% B at 40 min, to 90% B at 45 min, to 97% at 46 min,
was held for 4 min, and was followed by a 10-min postrun at 3%
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B. Mass detection was performed with an Agilent 6550 Accurate-
Mass Ion Funnel QTOF Chip-MS System operated in positive-
ion mode. Mass spectra were acquired in the 1,700 Da extended
dynamic range mode (2 GHz) using the following settings: ESI
capillary voltage, 1,960 V; fragmentor, 360 V; Octopole RF
peak, 750 V; drying gas, 13 L/min; drying temperature, 225 °C.
Data were acquired at a rate of 6 MS spectra per second and
3 MS/MS spectra per second in the mass ranges of m/z 295–1,700
for MS and 50–1,700 for MS/MS and stored in profile mode with
a maximum of 20 precursors per cycle with a threshold of 5,000
ions in a precursor abundance-based scan speed in a peptide
isotope model, with +2, +3, and above charge state preference,
with active exclusion after 1 spectra, and released after 0.15 min.
Fragmentation energy was applied at a slope of 3.0 V/100 Da with
a 3.0 offset. Mass accuracy was maintained by using internal ref-
erence ion m/z 1221.9906, in positive mode.
Data Processing. Agilent MassHunter Workstation software was
used for data acquisition and processing, and Agilent Spectrum
Mill MS Proteomics Workbench was used for database searching,
with the false discovery rate set at 1% (see Ravindra et al.,
2015, for details) (52). The data were additionally processed
with X!Tandem. Reverse/random database searches and manual
inspection of spectra were used to validate the peptide/protein
identifications. BSA standards were run daily for quality control.
Three biological and two technical replicate experiments were
performed, and detection of SNO-peptides in at least two was
required for identification. In addition, our criteria for identifi-
cation of SNO-proteins required detection of two or more tryptic
peptides per SNO-protein using approach A and the SNO-Cys
site-specific peptide identification using approach B. Using the
Spectrum Mill search engine (B.04.00.127, Agilent Technolo-
gies), raw MS/MS spectra were processed to extract MS/MS
spectra and searched against the SwissProt database. During
searching, the following parameters were used: carbamidome-
thylation as a fixed modification; trypsin; maximum of two
missed cleavages; precursor mass tolerance, ±20 ppm; product
mass tolerance, ±50 ppm; and maximum ambiguous precursor
charge, 4. Data were evaluated, and protein identifications were
considered significant if the following confidence thresholds
were met: protein score, >13; individual peptide scores of at
least 10; and Scored Peak Intensity, 60%. For approach B (SNO-
site identification), methionine oxidation, N-ethylmaleimide on
Cys, carbamidomethyl on Cys, N-ethylmaleimide + H2O on Cys,
and protein N terminus acetylation were set as variable PTMs.
Minimal peptide length was set to six amino acids, and a maxi-
mum of two missed cleavages was allowed. Peptide sequence and
fragmentation spectrum information were visualized using Scaffold
software (v.3.6, Proteome Software, Inc.) with the imported peptide
hits from Spectrum Mill.
Label-Free Quantitation Using Precursor Intensity with Scaffold Q+.
Precursor intensity was used for the fold-change quantitation of
common proteins detected in cortical and hippocampal samples.
Themethod is to work backward from the peptides that have been
identified through their MS/MS spectra and compare the in-
tensities of theMS peaks fromwhich they were derived. Precursor
intensity quantitation is based on the principle that the area of the
peak in theMS1 chromatogram provides a measure of the relative
abundance of the corresponding peptide in the sample. Peptides
are identified based on their MS/MS spectra, and then the cor-
responding MS1 peaks are identified in each LC–MS/MS run.
The areas under these peaks are calculated and normalized, and
their ratios are used as a measure of the relative abundance of
the peptides in different samples by Scaffold Q+ (Proteome
Software, Inc.). Relative quantities of proteins are estimated by
combining the precursor intensities of the constituent peptides.
Using the quantitative values based on precursor intensity, fold
changes were calculated by selecting control samples as the
reference using Scaffold.
Bioinformatics. To assess functional enrichment, the lists of SNO-
proteins were submitted to DAVID (https://david.ncifcrf.gov)
(34, 53). “Fold enrichment” was defined as the number of pro-
teins detected in the sample compared with the total number of
proteins expected in the mouse or human proteome in each GO
BP and pathway. P values for term enrichment were calculated
using the right-sided hypergeometric test. GO and KEGG path-
way enrichment (P < 0.05) analyses were performed by using the
functional annotation tool in DAVID. The consensus sequence
motifs of SNO-Cys were visualized by pLogo, a linear sequence
prediction algorithm based on their statistical significance (P <
0.05). Motif_x was used to align the Cys-containing peptide se-
quence for pLogo analysis (45).
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Method Number of 
total SNO-sites 
Number of total 
SNO-proteins 
Number of SNO-
sites in controls 
Number of SNO-
proteins in controls 
Organism details Brain region Reference 
SNOTRAP 313 251 Mouse; 
CK-p25; p25 (control) 
Cortex, hippocampus 
and cerebellum 
Current study 
BST and SNOSID 249 138 141 100 Mouse;  
hAPP mice; FVB (control) 
Whole brain 
(synaptosomal fraction) 
Zareba-Koziol  et al. 
(32) 
Phenylmercury
(MRC) 
163 119 163 119 Mouse; 
C57BL/6J 
Whole brain Doulias et. al. (30) 
SNOSID 68 56 68 56 Rat; 
Purchased from Pel-Freez
Cerebellum (GSNO-
treated) 
Hao et al. (16) 
Immunoprecipitation
/BST 
74 45 74 45 Human; 
AD patients (mean age 72 yr) 
Cortex, hippocampus, 
substantia nigra,  
Zahid et al. (31) 
116 152 
Fig. S1. Site-specific identification of SNO-protein. (A) Schematic for selective tagging of protein S-nitrosothiols using the biotin-SNOTRAP (b-SNOTRAP) probe. The
SNOTRAP reagent directly reacts with the –SNO group to yield an azaylide intermediate, which rearranges to form the disulfide–iminophosphorane compound.
(B) Representative MS/MS spectra for SNO-Cys150 of GAPDH and SNO-Cys284 of GPHN (SNO-Cys is highlighted in red). (C) Representative MS1 spectrums of GAPDH
(monoisotopicm/z 944.4688,MH+error 0.1 ppm) andGPHN (monoisotopicm/z 565.2814,MH+ error 0.2 ppm) identified in cortexwith low ppmmass error. (D) Representative
total ion chromatograms (TICs) after b-SNOTRAP capture showing ion intensity of untreated (black), TCEP-treated (red), UV-treated (green), and ascorbate-Cu–treated (blue)
samples. Chromatogram corresponding to TCEP treatment was plotted with a y axis offset of 1E4. (E) Representative Western blot of total b-SNOTRAP–captured proteins of
untreated (cortex control) and TCEP-treated samples. (F) Current methodologies used for detection of SNO-peptides and SNO-Cys sites (16, 30–32).
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Fig. S2. Altered SNO-proteins during early neurodegeneration. (A) SNO-proteins identified by MS were validated by SNOTRAP Western blot analysis. Rep-
resentative Western blot of SNO-Synaptophysin, SNO-GAPDH, and SNO-GSK3β in control and CK-p25 mice following 2-wk induction (n = 2). (B) Neuronal
proteins previously identified as S-nitrosated that were not in our MS datasets were examined by SNOTRAP Western blot. Representative Western blot of SNO-
PTEN, SNO-Cdk5, SNO-Stargazin, SNO-HDAC2, and SNO-PSD95 in control and CK-p25 mice following 2-wk induction (n = 2). (C) Linear motif generated by
pLOGO using published sequences that flank SNO-Cys sites detected in C57BL/6 wild-type mice (47).
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and CK-p25 mice. The ✔ symbol in the last column indicates the detection of the SNO-peptide using both Approach A and B according to tissue 
and genotype. SPI %, scored peak intensity obtained with Approach B. Hipp, hippocampus.	  
      
Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Cnp P16330 2',3'-cyclic-nucleotide 3'-phosphodiesterase 76.9 C111c LDEDLAGY C# RR ✓ 
 
✓ 
 
✓ 
 
Cnp P16330 2',3'-cyclic-nucleotide 3'-phosphodiesterase 71.3 C157c LD C# AQLKEK ✓ 
     
Ado Q6PDY2 2-aminoethanethiol dioxygenase 68.7 C225c EASGSA C# DLPR ✓ ✓ ✓ ✓ 
 
✓ 
Rps27l Q6ZWY3 40S ribosomal proein S27-like 74.8 C77c LTEG C# SFR ✓ ✓ ✓ ✓ 
 
✓ 
Rps28 P62858 40S ribosomal protein S28 76.3 C27c TGSQGQ C# TQVR 
  
✓ ✓ 
  Rpl10l P86048 60S ribosomal protein L10-like 83.1 C195c LIPDG C# GVK ✓ ✓ ✓ ✓ ✓ 
 Aco2 Q99KI0 Aconitate hydratase, mitochondrial 66.5 C385c VGLIGS C# TNSSYEDMGR ✓ 
   
✓ 
 Adss P46664 Adenylosuccinate synthetase isozyme 2 
 
C18c SISESSPAATSLPNDG C# GRPR ✓ 
     Arfgap1 Q9EPJ9 ADP-ribosylation factor GTPase-activating protein 1 69.9 C350c SPSSDSWT C# ADASTGRR ✓ 
     Mllt4 Q9QZQ1 Afadin 72.2 C1700c DYEPPSLSSAP C# APPPPPQR ✓ 
     Acan Q61282 Aggrecan core protein 68.5 C220c EG C# YGDKDEFPGVR ✓ 
     Cap1 P40124 adenylyl cyclase-associated protein 1 50.8 C426c NSLDC# EIVSAK ✓ 
     Add1 Q9QYC0 Alpha-adducin 87.6 C430c YSDVEVPASVTGHSFASDGDSGT C# SPLR ✓ 
     Add1 Q9QYC0 Alpha-adducin 67.3 C525c TAGPQSQVL C# GVMMDR ✓ 
     Eno1 P17182 Alpha-enolase 83.7 C399c TGAP C# RSER ✓ 
 
✓ ✓ ✓ ✓ 
Fto Q8BGW1 Alpha-ketoglutarate-dependent dioxygenase FTO 64.2 C184c AGVGPS C# DDEVDLKSR ✓ 
     Man2c1 Q91W89 Alpha-mannosidase 2C1 56 C222c SFQALHTANQMVNI C# DPAQPETYPAAK ✓ 
     Ank2 Q8C8R3 Ankyrin-2 70.2 C1538c SGT C# MRDEGR ✓ ✓ ✓ ✓ ✓ 
 Amer2 Q8CCJ4 APC membrane recruitment protein 2 61.7 C665c AAA C# HDSAK ✓ 
 
✓ ✓ 
 
✓ 
Agap2 Q3UHD9 
Arf-GAP with GTPase, ANK repeat and PH domain-
containing protein 2 65.5 C805c ALSTD C# TPSGDLSPLSR ✓ 
     As3mt Q91WU5 Arsenite methyltransferase 58.3 C33c TSADLQTNA C# VTR ✓ 
     Asphd1 Q2TA57 Aspartate beta-hydroxylase domain-containing protein 1 71.9 C95c AGGVSGMPDV C# SQTGPR ✓ 
     Astn1 Q61137 Astrotactin-1 78.1 C278c TLDSLQG C# NEK ✓ ✓ ✓ 
   Ntrk2 P15209 BDNF/NT-3 growth factors receptor 94.3 C176c SSPDTQDLY C# LNESSK ✓ ✓ 
    Ntrk2 P15209 BDNF/NT-3 growth factors receptor 72.2 C45c IW C# TEPSPGIVAFPR ✓ 
     Hexb P20060 Beta-hexosaminidase subunit beta 83.1 C288c NLLTP C# YNQK ✓ 
     Hexb P20060 Beta-hexosaminidase subunit beta 80.3 C530c GIAAQPLYTGY C# NYENKI ✓ 
     Bcas1 Q80YN3 Breast carcinoma-amplified sequence 1 homolog 89.2 C389c S C# SPPPPPPEPTSEGR ✓ ✓ ✓ ✓ ✓ ✓ 
Bcas1 Q80YN3 Breast carcinoma-amplified sequence 1 homolog 57.1 C574c EPAP C# VQPPTVEANAMQTGDKTPK ✓ ✓ ✓ ✓ ✓ ✓ 
Bcas1 Q80YN3 Breast carcinoma-amplified sequence 1 homolog 89.7 C318c ADSV C# DGHAAGQK ✓ ✓ ✓ ✓ ✓ ✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Bcan Q61361 Brevican core protein 93.5 C692c SWEEAESQ C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Bcan Q61361 Brevican core protein 67.9 C56c 
IGATQLRGVLGGALAIP C# 
HVHHLRPPHSRR ✓ 
     C2cd5 Q7TPS5 C2 domain-containing protein 5 66.4 C884c SAPP C# ASPTVGVVK ✓ 
     
Pde1b Q01065 
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide 
phosphodiesterase 1B 64.5 C16c SPPEMLESD C# PSPLELK ✓ 
     Camkk1 Q8VBY2 Calcium/calmodulin-dependent protein kinase kinase 1 41.1 C122c VAISDTED C# VQLNQYK ✓ 
     Camkk2 Q8C078 Calcium/calmodulin-dependent protein kinase kinase 2 72 C548c AGP C# GGGGSALVK ✓ ✓ 
  
✓ 
 Camk2a P11798 
Calcium/calmodulin-dependent protein kinase type II 
subunit alpha 88.3 C280c STVAS C# MHR ✓ ✓ ✓ ✓ ✓ 
 Camk2a P11798 
Calcium/calmodulin-dependent protein kinase type II 
subunit alpha 59 C289c QETVD C# LK ✓ ✓ ✓ ✓ ✓ 
 
Camk2b P28652 
Calcium/calmodulin-dependent protein kinase type II 
subunit beta 71.1 C35c L C# TGHEYAAK ✓ 
 
✓ 
 
✓ 
 Camsap2 Q8C1B1 Calmodulin-regulated spectrin-associated protein 2 76.8 C649c EALSP C# PSTISTK ✓ 
   
✓ 
 Prkacb P68181 cAMP-dependent protein kinase catalytic subunit beta 81.1 C349c  C# GKEF C# EF 
 
✓ 
    Arpp21 Q9DCB4 cAMP-regulated phosphoprotein 21 93.3 C71c SLAV C# EESSAR ✓ ✓ ✓ ✓ 
  Cnr1 P47746 Cannabinoid receptor 1 79.3 C450c AAES C# IKSTVK ✓ ✓ 
  
✓ ✓ 
Ca4 Q64444 Carbonic anhydrase 4 56.3 C35c SS C# LGPEK 
    
✓ ✓ 
Ceacam1 P31809 Q925P2 
Carcinoembryonic antigen-related cell adhesion 
molecule 1 81.5 C217c TLTLLNVTRNDTGPYV C# ETR 
    
✓ 
 Caskin1 Q6P9K8 Caskin-1 95.2 C1361c AAASVVSGPPVASD C# ASPGDSAR ✓ 
     Ctnnd2 O35927 Catenin delta-2 70.5 C506c QLQY C# ASVDSPYSK ✓ 
     Ctsl P06797 Cathepsin L1 23 C211c DGS C# KYR 
     
✓ 
Cadm2 Q8BLQ9 Cell adhesion molecule 2 60 C248c IIPSTPFPQEGQALTLT C# ESK ✓ 
     Cadm3 Q99N28 Cell adhesion molecule 3 71.1 C150c EKETATLN C# QSSGSKPAAQLTWR ✓ 
   
✓ 
 Cadm4 Q8R464 Cell adhesion molecule 4 83.0 C145c EQAVEGGEVELS C# LVPR ✓ 
     Cnbp P53996 Cellular nucleic acid-binding protein 61 C159c TSEVN C# YR ✓ ✓ ✓ ✓ 
 
✓ 
Cep170 Q6A065 Centrosomal protein of 170 kDa 80.8 C211c SQEAGASG C# STEAK     
  
✓ ✓ 
Cep170 Q6A065 Centrosomal protein of 170 kDa 70.2 C625c STS C# TTSLASQGER ✓ ✓ 
  
✓ ✓ 
Chmp5 Q9D7S9 Charged multivesicular body protein 5 70.2 C20c APPPSLTD C# IGTVDSR ✓ 
     Cspg5 Q71M36 Chondroitin sulfate proteoglycan 5 85.4 C560c LEGGKGDQDDLGVN C# LQNNLT ✓ 
     Clasp2 Q8BRT1 CLIP-associating protein 2 71.6 C968c KEDGDTI C# SGPGMSDPR ✓ 
     Cfl1 P18760 Cofilin-1 76.9 C80c MLPDKD C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Csde1 Q91W50 Cold shock domain-containing protein E1 56.1 C106c MNGQVV C# AVPHNLESK ✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Cplx1 P63040 Complexin-1 70.7 C105c KAIPPG C# GDEPEEEDESILDTVIK ✓ 
     Cplx2 P84086 Complexin-2 86.8 C90c AALEQP C# EGSLTRPK ✓ ✓ 
 
✓ ✓ ✓ 
Cntn1 P12960 Contactin-1 80.3 C65c VSLN C# R 
  
✓ ✓ ✓ 
 Cntnap1 O54991 Contactin-associated protein 1 81.8 C1251c VQGELSESN C# GAMPR ✓ ✓ 
    Cpne6 Q9Z140 Copine-6 64.7 C66c S C# SSPVFSR 
  
✓ ✓ 
  Coro1c Q9WUM4 Coronin-1C 71.1 C424c SELS C# APK 
 
✓ ✓ 
   Cul2 Q9D4H8 Cullin-2 62.3 C266c VIHE C# QQR 
  
✓ 
   Uqcrh P99028 Cytochrome b-c1 complex subunit 6, mitochondrial 87.9 C51c LEL C# DNR ✓ ✓ ✓ ✓ ✓ ✓ 
Uqcrh P99028 Cytochrome b-c1 complex subunit 6, mitochondrial 74.2 C79c DH C# VAHK ✓ ✓ ✓ ✓ ✓ ✓ 
Uqcrh P99028 Cytochrome b-c1 complex subunit 6, mitochondrial 64.6 C35c EH C# EQLEK ✓ ✓ ✓ ✓ ✓ ✓ 
Cox6b1 P56391 Cytochrome c oxidase subunit 6B1 72.2 C54c GGDVSV C# EWYR ✓ 
     Hccs P53702 Cytochrome c-type heme lyase 82.8 C70c AYDYVE C# PVTGAR ✓ 
     Cyfip2 Q5SQX6 Cytoplasmic FMR1-interacting protein 2 82.5 C1253c  C# FQPPIHQSLATT C#  ✓ 
     Dmtn Q9WV69 Dematin 59.2 C84c E C# SLSPK 
 
✓ 
    Dsg1a Q61495 Desmoglein-1-alpha 56.9 C702c nSMRE C# R   ✓ 
    Dstn Q9R0P5 Destrin 58 C23c  C# STPEEIKKR 
    
✓ 
 Rasd1 O35626 Dexamethasone-induced Ras-related protein 1 72.8 C214c VSVQY C# DVLHkk ✓ 
     Dpysl2 O08553 Dihydropyrimidinase-related protein 2 96.9 C504c GLYDGPV C# EVSVTPK ✓ 
 
✓ ✓ ✓ ✓ 
Dlgap3 Q6PFD5 Disks large-associated protein 3 85.4 
C103c 
C106c MYPGQGPFDT C# ED C# VGHPQGK ✓ 
   
✓ 
 Dbnl Q62418 Drebrin-like protein 76.8 C127c AEEDVEPE C# IMEK ✓ 
     
Map2k7 Q8CE90 
Dual specificity mitogen-activated protein kinase kinase 
7 57.5 C296c SAG C# AAYMAPER 
    
✓ 
 Huwe1 Q7TMY8 E3 ubiquitin-protein ligase HUWE1 58.4 C3361c TKETN C# ESDRER ✓ 
     Nedd4 P46935 E3 ubiquitin-protein ligase NEDD4 90.6 C365c LAV C# GNPATSQPVTSSNHSSR ✓ 
   
✓ 
 Erc1 Q99MI1 ELKS/Rab6-interacting/CAST family member 1 73.3 C258c TGEP C# VAELTEENFQR ✓ 
     Eef1g Q9D8N0 Elongation factor 1-gamma 91.4 C266c AAAPAPEEEMDE C# EQALAAEPK ✓ 
     Tufm Q8BFR5 Elongation factor Tu, mitochondrial 76.9 C127c HYAHTD C# PGHADYVK ✓ 
     Gpr37l1 Q99JG2 Endothelin B receptor-like protein 2 87.1 C481c ESPPLLPLGTP C#  ✓ ✓ ✓ ✓ ✓ ✓ 
Gpr37l1 Q99JG2 Endothelin B receptor-like protein 2 85.7 C203c LLGDVS C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Edc3 Q8K2D3 Enhancer of mRNA-decapping protein 3 37.50 C137c SQDVAISPQQQ C# SK ✓ 
     Echs1 Q8BH95 Enoyl-CoA hydratase, mitochondrial 73.8 C111c TFQD C# YSSK 
 
✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Epha6 Q62413 Ephrin type-A receptor 4 59.2 C4c TAAGYGDFSEPLEV ✓ ✓ 
    Slc1a3 P56564 Excitatory amino acid transporter 1 57.3 C375c C# LEENNGVDKR 
    
✓ ✓ 
Slc1a2 P43006 Excitatory amino acid transporter 2 94.8 C561c SAD C# SVEEEPWKRE ✓ ✓ ✓ ✓ ✓ ✓ 
Fbxl16 A2RT62 F-box/LRR-repeat protein 16 87.4 C47c NRP C# QPPPPPTLPPPSLATPLSR ✓ 
     Fxyd7 P59648 FXYD domain-containing ion transport regulator 7 65.8 C66c S C# KSELPSSAPGGGGV ✓ 
     Gprin1 Q3UNH4 G protein-regulated inducer of neurite outgrowth 1 72.3 C174c VDMP C# SSKVDIVSPGGDNAGSLR ✓ 
     Eno2 P17183 Gamma-enolase 60.5 C399c  TGAP C# RSER     ✓  ✓     
Gja1 P23242 Gap junction alpha-1 protein 75.8 C298c LVTGDRNNSS C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Gja1 P23242 Gap junction alpha-1 protein 80.5 C260c SDPYHATTGPLSPSKD C# GSPK ✓        ✓   
Gphn Q8BUV3 Gephyrin 79.9 C284c LSTAS C# PTPK ✓ 
 
✓ 
 
✓ ✓ 
Grid2 Q61625 Glutamate receptor ionotropic, delta-2 76.1 C131c SG C# GLTR 
    
✓ ✓ 
Grin1 P35438 Glutamate receptor ionotropic, NMDA 1 71.4 C798c YQE C# DSR ✓ ✓ ✓ ✓ 
 
✓ 
Grin2b Q01097 Glutamate receptor ionotropic, NMDA 2B 60.2 C436c NTVP C# QKR ✓ 
 
✓ ✓ 
  Gfpt1 P47856 Glutamine-fructose-6-phosphate aminotransferase 1 35.7 C262c VDSTT C# LFPVEEK ✓ 
     Glul P15105 Glutamine synthetase 90.2 C49c TLD C# EPK ✓ ✓ ✓ ✓ ✓ ✓ 
Gapdh P16858 Glyceraldehyde-3-phosphate dehydrogenase 89.7 C150c IVSNAS C# TTN C# LAPLAK ✓ 
 
✓ 
 
✓ ✓ 
Gsk3b Q9WV60 Glycogen synthase kinase-3 beta 56.7 C14c TTSFAES C# KPVQQPSAFGSMK ✓ 
     
Gpc1 
Q9QZF2 
P51655 
Q9R087 Glypican-1 65 C32c S C# SEVR 
 
✓ 
    Gprasp1 Q5U4C1 G-protein coupled receptor-associated sorting protein 1 64.5 C535c SVGVN C# EkMPK ✓ ✓ ✓ ✓ ✓ ✓ 
Gnao1 P18872 Guanine nucleotide-binding protein G(o) subunit alpha 76.6 C108c MV C# DVVSR ✓ 
 
✓ 
 
✓ 
 Hpx Q91X72 Hemopexin 70.9 C458c SLPQPQKVNSILG C# SQ ✓ 
     Hdgf P51859 Hepatoma-derived growth factor 76.3 C12c QKEYK C# GDLVFAK 
    
✓ 
 
Hpcal1 P62748 Hipocalcin-like protein 1 55.3 C185c LLQ C# DPSSASQF ✓ 
  
✓ 
 
✓ 
Homer3 Q99JP6 Homer protein homolog 3 79 C311c SME C# NLEEAR 
    
✓ ✓ 
Hapln1 Q9QUP5 Hyaluronan and proteoglycan link protein 1 78.4 C327c  C# SPTEAAVR 
 
✓ ✓ ✓ 
  
N/A P01837 Ig kappa chain C region 56.4 C106c SFNRNE C#  ✓ 
     Igsf21 Q7TNR6 Immunoglobulin superfamily member 21 76.9 C116c ISDNGPYE C# HVGIYDR ✓ 
     Igsf8 Q8R366 Immunoglobulin superfamily member 8 58.6 C184c LTVHEGQELALG C# LAQTK ✓ 
   
✓ 
 Itpka Q8R071 Inositol-trisphosphate 3-kinase A 55.2 C19c GAGP C# SPGLER ✓ 
     Itgav P43406 Integrin alpha-V 52.3 C172c  TVEYAP C# R 
  
✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Icam5 Q60625 Intercellular adhesion molecule 5 94 C607c VE C# VGSEGASEGIVLPLVSSNSGPR ✓ ✓ ✓ ✓ 
  Icam5 Q60625 Intercellular adhesion molecule 5 63.8 C431c SWTWPEGPEQTLH C# EAR ✓ 
     Icam5 Q60625 Intercellular adhesion molecule 5 56.6 C551c  C# EAINAR 
 
✓ 
 
✓ 
  Icam5 Q60625 Intercellular adhesion molecule 5 80.7 C724c  C# VATNAHGTDSR ✓ ✓ ✓ ✓ 
  Icam5 Q60625 Intercellular adhesion molecule 5 92.1 C415c LDDLD C# PR ✓ ✓ ✓ ✓ 
  Iqsec1 Q8R0S2 IQ motif and SEC7 domain-containing protein 1 82 C904c A C# LDDSYASGEGLKR ✓ 
     Iqsec2 Q5DU25 IQ motif and SEC7 domain-containing protein 2 56.8 C616c QLVYEADG C# SPHGTLK ✓ 
     Iscu Q9D7P6 
Iron-sulfur cluster assembly enzyme ISCU, 
mitochondrial 65.3 C70c NVGTGLVGAPA C# GDVMK ✓ 
     Asrgl1 Q8C0M9 Isoaspartyl peptidase/L-asparaginase 77.2 C317c LQAGIDL C# ETR ✓ ✓ ✓ ✓ ✓ ✓ 
Asrgl1 Q8C0M9 Isoaspartyl peptidase/L-asparaginase 85.9 C179c GAQNAD C# PK ✓ ✓ ✓ ✓ ✓ ✓ 
Asrgl1 Q8C0M9 Isoaspartyl peptidase/L-asparaginase 75.4 C326c TRDLP C#  ✓ ✓ ✓ ✓ ✓ ✓ 
Krt17 Q9QWL7 Keratin, type I cytoskeletal 17 60.1 
C29c 
C40c TS C# RLSGSLGAGS C# R ✓         ✓ 
Krt81 Q9ERE2 P97861 Keratin, type II cuticular Hb1 (Fragment) 55.3 C210c TK C# EEIk   
   
✓ 
 Fn3krp Q8K274 Ketosamine-3-kinase 63.8 C24c ATGHSGGG C# ISQGQSYDTDKGR 
    
✓ 
 Khdrbs1 Q60749 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 83.7 C19c S C# SKDPSGAHPSVR ✓ ✓ ✓ ✓ ✓ ✓ 
Kcp Q3U492 Kielin/chordin-like protein 76.9 C278c I C# Q C# LEGHIQ C# R ✓ 
     Kif1a P33173 Kinesin-like protein KIF1A 68.2 C609c TP C# AETPAEPVDWAFAQR ✓ 
     Lama1 P19137 Laminin subunit alpha-1 66.4 C3038c QN C# LSSR 
   
✓ 
  Llgl1 Q80Y17 Lethal(2) giant larvae protein homolog 1 68.3 C190c SVPDDYR C# GK 
     
✓ 
Luzp1 Q8R4U7 Leucine zipper protein 1 87.7 C561c GQVPGHASQGTQAVESS C# SK 
    
✓ 
 
Lgi1 Q9JIA1 Leucine-rich glioma-inactivating protein 1 70.7 C55c DNAL C# ENAR ✓ 
 
✓ ✓ ✓ 
 Lgi3 Q8K406 Leucine-rich repeat LGI family member 3 76 C52c DTAF C# VDSK 
 
✓ 
  
✓ ✓ 
Rltpr Q3V3V9 Leucine-rich repeat-containing protein 16C 71.2 C1227c TSPAPDILSLPEDP C# LGPR ✓ 
     Lrrc7 Q80TE7 Leucine-rich repeat-containing protein 7 69.7 C541c SM C# APLPVAAQSTTLPSLSGR ✓ 
     Lsamp Q8BLK3 Limbic system-associated membrane protein 76.2 C239c  C# EASAVPAPDFEWYRDDTR   ✓ 
   
✓ 
Lsamp Q8BLK3 Limbic system-associated membrane protein 78.7 C197c EQSGKYE C# K ✓ ✓ ✓ ✓ ✓ ✓ 
Lppr4 Q7TME0 Lipid phosphate phosphatase-related protein type 4 84.7 C605c NAEGSTVT C# TGSIR ✓ ✓ ✓ ✓ 
  Lppr4 Q7TME0 Lipid phosphate phosphatase-related protein type 4 66.7 C569c TVA C# NR ✓ ✓ ✓ ✓ 
  Ldha P06151 L-lactate dehydrogenase A chain 77.8 C84c IVSSKDY C# VTANSK 
  
✓ ✓ ✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
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Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Acsl4 Q9QUJ7 Long-chain-fatty-acid--CoA ligase 4 66.7 C157c NTIAIF C# ETR ✓ 
     Prnp P04925 Major prion protein 94.5 C213c VVEQM C# VTQYQK ✓ ✓ 
 
✓ ✓ ✓ 
Mdh1 P14152 Malate dehydrogenase, cytoplasmic 74.9 C154c SAPSIPKENFS C# LTR ✓ 
     Madd Q80U28 MAP kinase-activating death domain protein 83.6 C763c QTETGEGSV C# QR ✓ ✓ ✓ ✓ 
 
✓ 
Map7d1 A2AJI0 MAP7 domain-containing protein 1 84.2 C375c SASASPLTP C# SAPR ✓ ✓ 
  
✓ ✓ 
Map1a Q9QYR6 Microtubule-associated protein 1A 93.9 C2165c SAP C# GSLAFSGDR ✓  ✓ 
 
✓ 
 
✓ 
Map1a Q9QYR6 Microtubule-associated protein 1A 55.4 C2058c APISLSQDPSPPLNGSTTS C# GPDRR ✓ 
     Map1b P14873 Microtubule-associated protein 1B 93.6 C1913c TIKSP C# DSGYSYETIEK ✓ ✓ 
  
✓ ✓ 
Map1b P14873 Microtubule-associated protein 1B 91.9 C1936c TIKTPEDGGYT C# EITEK ✓ 
   
✓ 
 Map1b P14873 Microtubule-associated protein 1B 79.5 C1224c SALRDAY C# SEEKELK ✓ 
     Map1b P14873 Microtubule-associated protein 1B 61.8 C2037c SPDTSAY C# YETMEK ✓ ✓ 
    Map1b P14873 Microtubule-associated protein 1B 55 C2061c TPQASTYSYETSDR C# YTTEK ✓ 
     Map1a Q9QYR6 Microtubule-associated protein 1a 73.1 C2165c SAP C# GSLAFSGDR ✓  ✓    ✓     ✓ 
Map2 P20357 Microtubule-associated protein 2 62.7 C759c MP C# FPIESKEEEDKAEQAK ✓ 
     Map6 Q7TSJ2 Microtubule-associated protein 6 80 C500c SLYSEPFKE C# PKVEKPSVQSSKPK 
    
✓ 
 Mapre3 Q6PER3 Microtubule-associated protein RP/EB family member 3 71.8 C182c LSNVAPP C# ILRKNPPSAR ✓ 
   
✓ 
 Mapt P10637 Microtubule-associated protein tau 61.3 C151c EAT C# QPSGTRPEDIEK ✓ 
    
✓ 
Mtch2 Q791V5 Mitochondrial carrier homolog 2 79.5 C296c TY C# YDLR ✓ ✓ ✓ ✓ ✓ ✓ 
Tomm40 Q9QYA2 Mitochondrial import receptor subunit TOM40 homolog 80.8 C74c 
TPGAAASGAAAASEDGS C# G C# 
LPNPGTFEE C# HRK ✓ 
     Marc2 Q922Q1 MOSC domain-containing protein 2, mitochondrial 66.5 C74c GVSV C# ETE C# TDMGLR ✓ 
     Rnmt Q9D0L8 mRNA cap guanine-N7 methyltransferase 65.2 C37c LPENTPP C# QQVDQPK ✓ 
     Muc6 Q80T03 Mucin-6 56.9 C966c VLTENVI C# GkSGVT C# SR ✓ 
     Plp1 P60202 Myelin proteolipid protein 92.7 C201c TSASIGSL C# ADAR ✓ ✓ ✓ ✓ ✓ ✓ 
Plp1 P60202 Myelin proteolipid protein 75.2 C109c TTI C# GK   
 
✓ 
  
✓ 
Mag P20917 Myelin-associated glycoprotein 61.9 C488c VI C# TSR ✓ 
 
✓ 
 
✓ 
 Mog Q61885 Myelin-oligodendrocyte glycoprotein 83.5 C52c ALVGDEAELP C# R ✓ 
     Myadm O35682 Myeloid-associated differentiation marker 74 C273c SMDPS C# TR ✓ 
 
✓ ✓ ✓ 
 
Ndufs1 Q91VD9 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 88.5 C727c AVTEGAQAVEEPSI C#  ✓ 
    
✓ 
Ganab Q8BHN3 Neutral alpha-glucosidase AB 57.4 
C41c 
C47c T C# DESSF C# K ✓ 
     Ncam1 P13595 Neural cell adhesion molecule 1 95.4 C288c NVDKNDEAEYV C# IAENK ✓ ✓ ✓ ✓ 
 
✓ 
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Cortex Hipp Cerebellum 
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SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Ncam1 P13595 Neural cell adhesion molecule 1 80.2 C189c TDEGTYR C# EGR 
 
✓ 
  
✓ 
 Ncam2 O35136 Neural cell adhesion molecule 2 84.6 C380c LSDSGRYD C# EAASR ✓ 
     Ncam2 O35136 Neural cell adhesion molecule 2 63.8 C136c QGEDAEVV C# R ✓ 
     L1cam P11627 Neural cell adhesion molecule L1 55 C353c LD C# QVQGRPQPEITWR ✓ ✓ ✓ ✓ ✓ ✓ 
Nrxn1 Q9CS84 Neurexin-1 56.2 C679c QMAEIQSTAGVKPS C# SK ✓ 
     Ncald Q91X97 Neurocalcin-delta 82.7 C185c LLQ C# DPSSAGQF ✓ 
     Ncan P55066 Neurocan core protein 83.5 C1167c GTVL C# GPPPAVENASLVGVR ✓ ✓ 
    Ncan P55066 Neurocan core protein 66.8 C354c FDAY C# FR ✓ 
     Ncan P55066 Neurocan core protein 63 C279c AQ C# QR ✓ 
     Ncdn Q9Z0E0 Neurochondrin 81.9 C725c MAALEQ C# LSEP ✓ 
  
✓ 
 
✓ 
Scg5 P12961 Neuroendocrine protein 7B2 62.1 C130c TADDG C# LENAPDTAEFSR ✓ 
     Nfasc Q810U3 Neurofascin   93.3 C118c SGGRPEEYEGEYQ C# FAR ✓ 
     Nfasc Q810U3 Neurofascin 81.2 C63c DNILIE C# EAK ✓ ✓ 
 
✓ 
 
✓ 
Nrgn P60761 Neurogranin 73.1 C51c SGE C# GRKGPGPGGPGGAGGAR ✓ ✓ ✓ ✓ ✓ ✓ 
Nrgn P60761 Neurogranin 94.8 C51c SGE C# GR ✓ ✓ ✓ ✓ ✓ ✓ 
Nrcam Q810U4 Neuronal cell adhesion molecule 73.5 C519c DSTGTYT C# VAR ✓ ✓ ✓ ✓ 
 
✓ 
Nrcam Q810U4 Neuronal cell adhesion molecule 85.3 C62c ENIVIQ C# EAK ✓ ✓ ✓ ✓ 
 
✓ 
Negr1 Q80Z24 Neuronal growth regulator 1 77.7 C197c DQAGEYE C# SAENDVSFPDVKK ✓ 
     Hpca P84075 Neuron-specific calcium-binding protein hippocalcin 86.3 C185c LLQ C# DPSSASQF ✓ 
     Nptn P97300 Neuroplastin 92.7 C116c LTLEDSGTYE C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Nptn P97300 Neuroplastin 84.9 C258c SENKNEGQDAMMY C# K ✓ ✓ ✓ ✓ ✓ ✓ 
Nptn P97300 Neuroplastin 73.7 C217c AEDSGEYH C# VYHFVSAPK ✓ 
     Ntm Q99PJ0 Neurotrimin 93.5 C201c EQSGEYE C# SASNDVAAPVVR ✓ 
 
✓ 
  
✓ 
Slc1a4 O35874 P56564 Neutral amino acid transporter A 90.7 C355c  C# IEENNGVDKR 
  
✓ ✓ 
 
✓ 
Ovch2 Q7M761 Ovochymase-2 60.5 C265c GAWTLAGVTSWGLG C# GRSWRNnAR 
   
✓ 
  Cask O70589 Peripheral plasma membrane protein CASK 65.6 C684c VA C# IAMEK 
   
✓ 
  Prdx5 P99029 Peroxiredoxin-5, mitochondrial 75.4 C200c ALNVEPDGTGLT C# SLAPNILSQ ✓ 
     Prdx6 O08709 Peroxiredoxin-6 91.3 C47c DFTPV C# TTELGR ✓ 
     Pip5k1c O70161 
Phosphatidylinositol 4-phosphate 5-kinase type-1 
gamma 56.7 C581c ITVQVEPV C# GVGVVPK ✓ ✓ 
    
Phyhipl Q8BGT8 Q8K0S0 Phytanoyl-CoA hydroxylase-interacting protein-like 64.5 C369c T C# NISVGR   ✓ 
 
✓ ✓ ✓ ✓ 
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Cortex Hipp Cerebellum 
Gene 
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CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Pithd1 Q8BWR2 PITH domain-containing protein-1 36.9 C188c HEVTI C# NYESANPADHR ✓ 
     Adcyap1r1 P70205 
Pituitary adenylate cyclase-activating polypeptide type I 
receptor 80.2 C34c EQAM C# LER ✓ 
 
✓ ✓ ✓ ✓ 
Atp2b2 Q9R0K7 Plasma membrane calcium-transporting ATPase 2 94.4 C621c VIEPMA C# DGLR ✓ ✓ ✓ ✓ ✓ ✓ 
Atp2b2 Q9R0K7 Plasma membrane calcium-transporting ATPase 2 55.4 C628c TI C# VAYR 
    
✓ 
 Plxna4 Q80UG2 Plexin-A4 68.1 C103c IVQT C# NEPLASTNNVNK ✓ 
     Pcbp1 P60335 Poly(rC)-binding protein 1 91.9 C194c VMTIPYQPMPASSPVI C# AGGQDR ✓ ✓ 
  
    
 Pcbp1 
P60335 
Q61990 
P57722 Poly(rC)-binding protein 1 60.2 C54c INISEGN C# PER 
    
✓ ✓ 
Hcn2 O88703 
Potassium/sodium hyperpolarization-activated cyclic 
nucleotide-gated channel 2 55 C69c DSA C# TPGAAK 
     
✓ 
Atp12a Q9Z1W8 Potassium-transporting ATPase alpha 2 91.1 C367c KN C# LVK 
   
✓ ✓ ✓ 
Atp12a 
Q9Z1W8 
Q8VDN2 
Q6PIE5 
Q6PIC6 
Q9WV27 Potassium-transporting ATPase alpha  2 96.7 C716c LIIVEG C# QR 
   
✓ ✓ ✓ 
Gpr37 Q9QY42 Probable G-protein coupled receptor 37 43.1 C600c EMSTFASVGTH C#  ✓ 
     Gpr158 Q8C419 Probable G-protein coupled receptor 158 79.8 C1166c AEV C# PWEFEPLEQPNAER ✓ 
     Lrp1 Q91ZX7 Prolow-density lipoprotein receptor-related protein 1 70.5 C2518c ILQEDFT C# R ✓ 
 
✓ 
   Ptges2 Q8BWM0 Prostaglandin E synthase 2 58 C382c AIEEAPSVHHVNPS C# KD 
    
✓ 
 Bsn O88737 Protein bassoon 85.1 C1133c SS C# SEYSPSPSLDSEAETLDGGPTR ✓ 
     Fam114a2 Q8VE88 Protein FAM114A2 69.9 C490c TESST C# EPQSR ✓ 
     Phf24 Q80TL4 Protein KIAA1045 76.7 C334c LTEAPS C# SVSISHVGPIADSSPAASSSK ✓ 
     Prkce P16054 Protein kinase C epsilon type 68.1 C74c TNSPAWHDEFVTDV C# NGR ✓ 
     Prkcg P63318 Protein kinase C gamma type 90.4 C305c FEA C# NYPLELYER ✓ 
     Prkcg P63318 Protein kinase C gamma type 73.5 C150c SVPSL C# GVDHTERR ✓ 
   
✓ 
 Prkcg P63318 Protein kinase C gamma type 60.6 C133c  C# S C#  C# EMNVHRR ✓ 
   
✓ 
 Ndrg2 Q9QYG0 Protein NDRG2 82.7 C371c TLSQSSESGTLPSGPPGHTMEVS C#  ✓ ✓ 
    Ndrg3 Q9QYF9 Protein NDRG3 81.1 C375c HQTMEVS C#  ✓ ✓ ✓ ✓ 
 
✓ 
Odr4 Q4PJX1 Protein odr-4 homolog 56.2 
C274c 
C286c STATVQI C# SGSVNLRGnVK C# R 
    
✓ 
 Ppp1r1a Q9ERT9 Protein phosphatase 1 regulatory subunit 1A 72.5 C147c TQEQ C# GVEPR ✓ ✓ ✓ ✓ 
  Ppp1r1b Q60829 Protein phosphatase 1 regulatory subunit 1B 72.9 C148c GTVGQKPT C# GR ✓ ✓ ✓ ✓ ✓ 
 Ppp1r1b Q60829 Protein phosphatase 1 regulatory subunit 1B 61.4 C72c SKRPNP C# AYTPPSLK ✓ 
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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Pclo Q9QYX7 Protein piccolo 71.5 C1222c 
VASLA C# 
EGEQQPDTRPEDLPGATPQTLPKDR ✓      
Shisa9 Q9CZN4 Protein shisa-9 63.9 C397c LGIAESGS C# DPLGTR ✓ 
     Dnajc6 Q80TZ3 Putative tyrosine-protein phosphatase auxilin 46.3 C16c HYQTIQEAGDW C# VPSTEPK ✓ 
     Rab3gap1 Q80UJ7 Rab3 GTPase-activating protein catalytic subunit 42.2 C919c SG C# PEER 
    
✓ ✓ 
Rabl6 Q5U3K5 Rab-like protein 6 95.3 C501c VAPQQ C# SEPETK ✓ 
    
✓ 
Ralbp1 Q62172 RalA-binding protein 1 58.2 C622c GGIGPPP C# DGVLEVR ✓ 
     Rap1gap2 Q5SVL6 Rap1 GTPase-activating protein 2 57.1 C565c TR C# DSASSTPK ✓ 
     Syngap1 F6SEU4 Ras GTPase-activating protein SynGAP 93.7 C821c SSPAY C# TSSSDITEPEQK ✓ 
     Rtn1 Q8K0T0 Reticulon-1 77.4 C64c EL C# SGPAR ✓ ✓ ✓ ✓ ✓ ✓ 
Rtn3 Q9ES97 Reticulon-3 72.9 C559c V C# SAAPPSVLNETGFSLTVPASAK ✓ 
     Rtn3 Q9ES97 Reticulon-3 69.7 C344c TS C# TTESTGLDR ✓ ✓ ✓ ✓ 
  Rtn4 Q99P72 Reticulon-4 90.6 C319c SKDKEDLV C# SAALHNPQESPATLTK ✓ 
     Arhgap5 P97393 Rho GTPase-activating protein 5 58.4 C30c EPRPPSYTVSVVGLSGTEKDkGN C# GVGk 
 
✓ 
    Ryr2 E9Q401 Ryanodine receptor 2 38.9 C3008c EKEMVTSLF C# K ✓ 
     Atp2a2 O55143 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 80 C669c DA C# LNAR ✓ ✓ ✓ ✓ ✓ ✓ 
Atp2a2 O55143 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 83.9 C998c NYLEQPGKE C# VQPATK ✓ 
   
✓ ✓ 
Scrn1 Q9CZC8 Secernin-1 80 C324c AQSP C# FGDDDPAKKEPR ✓ 
   
✓ ✓ 
Sept6 Q9R1T4 Septin-6 65.2 C14c QVGED C# R ✓ 
     Sept7 O55131 Septin-7 64.4 C17c SVN C# GTMAQPK ✓ ✓ 
    Srr Q9QZX7 Serine racemase 85.5 C217c VYAAEPSNADD C# YQSK ✓ 
     Dclk1 Q9JLM8 Serine/threonine-protein kinase DCLK1 79.3 C276c YQDDFLLDESE C# R ✓ 
     Dclk2 Q6PGN3 Serine/threonine-protein kinase DCLK2 79 C287c YAQDDFVLDHSE C# R ✓ ✓ ✓ ✓ 
  Wnk2 Q3UH66 Serine/threonine-protein kinase WNK2 57 C1946c AVQTQQP C# SVR ✓ 
     Tf Q921I1 Serotransferrin 72.3 C472c S C# HTGVDR ✓ ✓ ✓ ✓ ✓ ✓ 
Tf Q921I1 Serotransferrin 75.1 C67c TSYPD C# IK ✓ ✓ ✓ ✓ 
  Tf Q921I1 Serotransferrin 84.4 C692c LLEA C# TFHKH   
  
✓ ✓ 
 Alb P07724 Serum albumin 76.4 C289c YM C# ENQATISSK ✓ 
   
✓ ✓ 
Sgip1 Q8VD37 SH3-containing GRB2-like protein 3-interacting protein 1 54.9 C402c E C# GLGQR 
  
✓ 
   Slc6a11 P31650 Sodium- and chloride-dependent GABA transporter 3 91.7 C607c TVTVND C# EAK  ✓  ✓ ✓   ✓ ✓   ✓ 
Atp1a3 Q6PIC6 Sodium/potassium-transporting ATPase subunit alpha-3 76.9 C49c KYNTD C# VQGLTHSK ✓ ✓ ✓ ✓ ✓ ✓ 
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CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Atp1a3 Q6PIC6 Sodium/potassium-transporting ATPase subunit alpha-3 90 C221c SPD C# THDNPLETR ✓ ✓ ✓ ✓ ✓ ✓ 
Atp1a3 Q6PIC6 Sodium/potassium-transporting ATPase subunit alpha-3 90.2 C42c MSVEEV C# RK ✓ ✓ ✓ ✓ ✓ ✓ 
Atp1a3 Q6PIC6 Sodium/potassium-transporting ATPase subunit alpha-3 83.5 C49c YNTD C# VQGLTHSK ✓ ✓ ✓ ✓ ✓ ✓ 
Atp1b1 P14094 Sodium/potassium-transporting ATPase subunit beta-1 89.5 C214c YNPNVLPVQ C# TGK ✓ 
   
✓ 
 Atp1b1 P14094 Sodium/potassium-transporting ATPase subunit beta-1 55.7 C277c VE C# K ✓ ✓ ✓ ✓ ✓ ✓ 
Atp1b2 P14231 Sodium/potassium-transporting ATPase subunit beta-2 68.2 C129c NDV C# RPGR ✓ ✓ ✓ ✓ ✓ ✓ 
Sf1 Q64213 Splicing factor 1 67.7 C279c SITNTTV C# TK 
    
✓ 
 Srcin1 Q9QWI6 SRC kinase signaling inhibitor 1 86 C1017c AIPDLD C# ASK ✓ ✓ 
 
✓ 
  Stub1 Q9WUD1 STIP1 homology and U box-containing protein 1 58.2 C200c AQQA C# IEAK   
    
✓ 
sygp1 Q8CHC4 Synaptojanin-1 63.8 C1051c TSP C# QSPTVPEYSAPSLPIRPSRAPSR ✓ 
     
syp Q62277 Synaptophysin 86.6 C87c LHQVYFDAPS C# VK ✓ ✓ ✓ ✓ ✓ ✓ 
Syp Q62277 Synaptophysin 73.1 C184c MATDPENIIKEMPM C# R ✓ ✓ 
    Syp Q62277 Synaptophysin 61.5 C191c QTGNT C# K ✓ ✓ ✓ ✓ ✓ ✓ 
Syp Q62277 Synaptophysin 78.9 C184c EMPM C# R ✓ ✓ ✓ ✓ ✓ ✓ 
Snap47 Q8R570 Synaptosomal-associated protein 47 62.4 C330c G C# TPHRELPTGGQEGEQLQLQK 
    
✓ 
 Snph Q80U23 Syntaphilin 62.3 C43c DAYGTSSLSSSSNSGS C# K ✓ 
     Stxbp5l Q5DQR4 Syntaxin-binding protein 5-like 72 C608c SLSGSTNTVSSEGVTKDSIP C# LSVK ✓ 
     Tcp1 P11983 T-complex protein 1 subunit alpha 82.2 C357c I C# DDELILIK ✓ 
     Tecpr1 Q80VP0 Tectonin beta-propeller repeat-containing protein 1 72.4 C480c SDE C# RGPASTPAELPWTNIDLKEPK ✓ 
     Ercc2 O08811 
TFIIH basal transcription factor complex helicase XPD 
subunit 57.3 C134c  C# HSLTASYVR ✓ 
     Thop1 Q8C1A5 Thimet oligopeptidase 61.2 C687c GLQVEGSEAPA C#  ✓ 
     Tm2d2 Q8R0I4 TM2 domain-containing protein 2 32.7 C128c ALEGIE C# AS ✓ 
     Tceal3 Q8R0A5 Q8CCT4 Transcription elongation factor A protein-like 3 70.3 C142c E C# ADMTR ✓ ✓ ✓ ✓ 
 
✓ 
Tacc1 Q6Y685 Transforming acidic coiled-coil-containing protein 1 56.6 C479c KYEAQPLDLDA C# SQDEGAVISK ✓ 
     Tsn Q62348 Translin 76 C225c GFNKETAAA C# GEK 
   
  ✓ 
 
Tuba1a 
P68369 
P05213 
P68373 
P68368 Tubulin alpha-1A chain 78.1 C316c HGKYMA C#  C# LLYRGDVVPK ✓ 
  
✓ 
  Tubb2a Q7TMM9 Tubulin beta-2A chain 90.7 C354c TAV C# DIPPR ✓ ✓ ✓ ✓ ✓ ✓ 
Tubb2a Q7TMM9 Tubulin beta-2A chain 79.6 C303c NMMAA C# DPR ✓ ✓ ✓ ✓ ✓ ✓ 	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Cortex Hipp Cerebellum 
Gene 
Symbol 
UniprotKB 
Access # Entry name SPI % 
SNO-
Site Sequence (# denotes SNO-Cys site) 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
CK-
p25 Ctrl 
Tubb2a 
Q7TMM9 
Q9CWF2 
Q9ERD7 
P99024 
Q9D6F9 
P68372 Tubulin beta-2A chain 79.5 C12c MREIVHIQAGQ C# GNQIGAK ✓ ✓ ✓ ✓ ✓ ✓ 
Uchl1 Q9R0P9 Ubiquitin carboxyl-terminal hydrolase isozyme L1 61.6 C152c AK C# FEKNEAIQAAHDSVAQEGQ C# R ✓ 
     Uba52 P62984 Ubiquitin-60S ribosomal protein L40 71.9 C110c AVN C# R 
  
✓ 
   Ube2o Q6ZPJ3 Ubiquitin-conjugating enzyme E2 O 79.1 C593c VQS C# PDPAVYGVVQSGDHVGR ✓ 
     Uba5 Q8VE47 Ubiquitin-like modifier-activating enzyme 5 71.2 C33c SGGDGH C# GR ✓ ✓ ✓ ✓ 
 
✓ 
Ubxn2b Q0KL01 UBX domain-containing protein 2B 73.7 C54c STPAT C# R ✓ 
 
✓ 
   Vcam1 P29533 Vascular cell adhesion protein 1 71.3 C668c QAQLQDAGIYE C# ESKTEVGSQLR ✓ 
     Vcan Q62059 Versican core protein 86.9 C3258c GTVA C# GQPPVVENAK ✓ 
    
✓ 
Vcan Q62059 Versican core protein 65.4 C217c EG C# YGDMMGK ✓ 
     Slc32a1 Slc32a1 Vesicular inhibitory amino acid transporter 26.10 C70c SEGEP C# GDEGAEAPVEGDIHYQR ✓ 
     Vdac2 Q60930 Voltage-dependent anion-selective channel protein 2 95.1 C48c S C# SGVEFSTSGSSNTDTGK ✓ 
    
✓ 
Cacna2d3 Q9Z1L5 
Voltage-dependent calcium channel subunit alpha-
2/delta-3 86.8 C969c LKQTLEP C# DTEYPAFVSER ✓ 
     Cacna1a P97445 
Voltage-dependent P/Q-type calcium channel subunit 
alpha-1A 71.6 C2327c AAG C# ASPR 
 
✓ 
  
✓ 
 Atp6v1g1 Q9CR51 V-type proton ATPase subunit G 1 71.5 C69c EAAALGSHGS C# SSEVEKETR 
    
✓ 
 Wfdc1 Q9ESH5 WAP four-disulfide core domain protein 1 65.2 C80c  C# QADSE C# PR ✓ 
     	  
